ciml nk
Cell therapyexperimental
Clinical trial activity
9 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 23, 2017 (NCT03068819)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1
- Leukemia · Phase 1
- Leukemia, Myeloid · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Juvenile · Phase 1
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Ovarian Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07011004 | Phase 1 | May 30, 2025 | Genentech, Memorial Sloan-Kettering Cancer Center |
| NCT06321484 | Phase 1 | Oct 9, 2024 | Harvard University, ImmunityBio, Inc. |
| NCT06138587 | Phase 1 | May 31, 2024 | Harvard University |
| NCT06152809 | Phase 1 | Jan 31, 2024 | Harvard University, The Leukemia and Lymphoma Society |
| NCT05580601 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | University of Cincinnati |
| NCT04634435 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2020 | Biohaven Pharmaceuticals Inc., Harvard University |
| NCT04290546 | Phase 1 | Mar 31, 2020 | Altor Bioscience, Bristol-Myers Squibb, Harvard University, Miltenyi Biotec, Inc. |
| NCT04024761 | Phase 1 | Aug 31, 2019 | Dunkin Donuts, Harvard University |
| NCT03068819 | Phase 1/Phase 2 (Phase 2) | Oct 23, 2017 | Washington University in St. Louis |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 6 | 5 | 2 | 2019 |
| Altor Bioscience | For profit | 1 | 0 | 1 | 2020 |
| Biohaven Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2020 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
| Dunkin Donuts | For profit | 1 | 0 | 1 | 2019 |
| Genentech | For profit | 1 | 0 | 1 | 2025 |
| ImmunityBio, Inc. | For profit | 1 | 0 | 1 | 2024 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2020 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2017 |
12 organizations
Page 1 / 1